RANCHO SANTA MARGARITA, Calif., Dec. 18, 2002 (PRIMEZONE) -- BioCurex Inc. (OTCBB:BOCX) is pleased to announce the successful presentation of 6 communications related to its RECAF Technology at the annual meeting of the International Society of Oncodevelopmental Biology and Medicine (ISOBM) held in Boston MA., Fall 2002.
The 6 scientific reports appeared published in the September issue of the International Scientific Journal Tumor Biology (23.09.02). Dr. Moro, who presented the work stated: "The communications attracted a great deal of attention. We are putting RECAF on the scientific map. Furthermore, as a result of these presentations, we have arranged several collaborations with scientists and pharmaceutical companies in the USA, Europe and Japan to further validate our results. We are very excited because as more and more scientists get involved in RECAF, a cascade of publications is likely to happen that will allow us to reach the critical mass necessary for general acceptance of our technology as a medical tool."
BioCurex Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging and therapeutics. The technology identified a cancer market known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. Detailed information about BioCurex Inc. may be obtained from their website at http://www.biocurex.com.
Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.